Fortescue director uses medical cannabis to cope with pain afr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from afr.com Daily Mail and Mail on Sunday newspapers.
Zelira Therapeutics Ltd s commercialisation program to see launch of suite of new cannabinoid-based products over FY22 proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.
Zelira Therapeutics closes out FY21 with record cash receipts ahead of product launches
The cannabinoid medicines developer brought in more than A$300,000 from customers over FY21’s final quarter, marking the best quarterly result on record. Zelira has closed out the 2021 financial year with a record A$311,000 in cash receipts.
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has capped off the 2021 financial year with record cash receipts as it looks ahead to product launches later this year.
The cannabinoid medicines developer finished the June quarter with A$311,000 in cash receipts up 38% on the March quarter’s A$225,000 result.
In today’s quarterly report, Zelira chalked up the record receipts to sales growth across its SprinjeneCBD toothpaste line, clinical trial management and product licensing fees from partner Levin Health Limited.